data.navlin.com Open in urlscan Pro
162.208.118.10  Public Scan

Form analysis
1 forms found in the DOM

Name: mc-embedded-subscribe-form — POST https://submit.jotform.com/submit/210895427465060/

<form name="mc-embedded-subscribe-form" method="post" action="https://submit.jotform.com/submit/210895427465060/" target="_blank" class="ng-pristine ng-valid">
  <div>
    <input type="email" id="input_3" name="q3_email" aria-label="Your email address (required)" placeholder="Your email address" required="">
  </div>
  <div class="checkbox-widget">
    <input id="subs-agree" type="checkbox" required="">
    <label for="subs-agree">
      <svg class="sprite ico-checkbox">
        <use xlink:href="#ico-checkbox"></use>
      </svg> By subscribing, you agree to EVERSANA’s <a href="https://www.eversana.com/legal/terms-and-conditions-copayconnect/" target="_blank" rel="noopener">term &amp; conditions</a> and
      <a href="https://www.eversana.com/legal/privacy/" target="_blank" rel="noopener">privacy policy</a>. </label>
  </div>
  <div>
    <button type="submit"><svg class="sprite ico-footer-subs-arrow-right">
        <title>Subscribe</title>
        <use xlink:href="#ico-footer-subs-arrow-right"></use>
      </svg></button>
  </div>
</form>

Text Content

Navlin
 * Products
    * NAVLIN Price & Access Data
    * NAVLIN Price & Access Software
    * NAVLIN Insights
    * NAVLIN Daily

 * Thought Leadership
 * Contact

Login
Open the menu
Close the Menu Navlin
 * Home
 * NAVLIN Price & Access Data
 * NAVLIN Price & Access Softwate
 * NAVLIN Insights
 * Contact

Login
 * Eversana
 * LinkedIn


GOOD DECISIONS
START WITH THE MOST ACCURATE DATA

With Pricing and Reimbursement data in 100+ countries and 45+ HTA bodies, NAVLIN
Data is the industry's most powerful and comprehensive pricing and market access
database available.

Free Trial Book a Meeting
Features


THERE’S A REASON NAVLIN IS THE GOLD STANDARD FOR PRICING & MARKET ACCESS
DATABASES

Accurate Measured weekly, NAVLIN's data accuracy rating is greater than 99.8%
and is trusted daily by thousands of pricing and market access professionals.
Expert Support No more waiting for help! Our dedicated support team is available
24/7 via Email / Live Chat / Video to support you with any questions!
Coverage NAVLIN manages every product (ATC Code) in more than 100 countries and
provinces! Plus, we have complete historical coverage in most countries!
Comprehensive More than just pricing data, NAVLIN provides news & insights,
analytics, HTA, regulatory, clinical, and economic data in one consolidated
spot!
Real-time Updates Zero Lag! NAVLIN is updated in real time, providing our users
with the industries most accurate pricing and market access data.
Efficient Combining comprehensive pricing and market access data, one-click
insights, and expert support enables teams to focus on strategy and improved
decision-making.
Innovation Combining comprehensive pricing and market access data, one-click
insights, and expert support enables teams to focus on strategy and improved
decision-making.


MORE THAN 90% OF COMPANIES THAT TRY NAVLIN DATA SUBSCRIBE TO OUR SERVICES

Start your free trial of NAVLIN Data today!

Free Trial Book a Meeting


COMPREHENSIVE. BEAUTIFUL. AND EASY TO USE

Pricing Cost Of Treatment Reimbursement HTA Decisions Analytics News and
Insights Country Overviews Analogue ID


PRICING

NAVLIN delivers highly accurate data in real-time across 100+ countries (all
ATCs / therapeutic areas). Even more, NAVLIN has been collecting data in 50+
markets longer than any other vendor, making our historical coverage the most
expansive in the industry! From product launch to the latest price, we have it
all!




COST OF TREATMENT

NAVLIN’s zero-effort Cost of Treatment data is available at the indication level
across all therapeutic areas. The dosing regimen of each record is pre-populated
within NAVLIN and sourced from country-specific prescribing guidelines. Users
have the ability to override Cost of Treatment outputs by changing the base
dosing regimen to create their own scenarios!




REIMBURSEMENT

NAVLIN includes standardized reimbursement decision details at the indication
level for maximum accuracy. Key reimbursement data include: status, date, line
of therapy, restrictions, and much more!

Our one-click insights allow users to quickly understand reimbursement trends,
approval sequence, and compare across competitors!




HTA DECISIONS

NAVLIN HTA provides real-time updates across 45+ bodies, including detailed
information on benefits assessments and economic evaluations. Data include
economic modeling results, clinical trial evidence, and economic and clinical
drivers.

In addition, pricing, regulatory data, epidemiology, and managed entry
agreements are included in one place!




ANALYTICS

Whether you want to instantly compare drug prices across markets or analyze
historical pricing trends and what key events drove the outcome-it’s possible
with NAVLIN’s Insights module in just a few clicks!

NAVLIN offers many pre-defined reports, with the ability to quickly generate
your own graphical or tabular reports.




NEWS AND INSIGHTS

Trusted by many organizations as its primary news source, NAVLIN Daily covers
global pricing and market access news without all the noise. NAVLIN Daily
connects the dots on how the day’s biggest stories affect your business and
keeps you up-to-date and informed on key stories from around the world.




COUNTRY OVERVIEWS

Access detailed country overviews across 85+ markets on processes, policies,
regulatory system, P&R system, HTA and reimbursement process, price setting,
distribution margins, managed entry agreements, early access, and much more!

Plus, a built-in IRP Rule Matrix, interactive maps, and other reports make it
easy to find exactly what you’re looking for!




ANALOGUE ID

Finding a good analogue requires the best and most accurate data. Analogue ID
leverages NAVLIN’s expansive data set and proprietary search algorithm to guide
you quickly and confidently to the perfect analogue in seconds!

NAVLIN Analogue ID incorporates data elements from Pricing, Cost of Treatment,
HTA Decisions, Key Dates, Regulatory, Clinical Trials, Pipeline data, Sales
forecasts, and more to give you the best results.


Real quotes from real clients.


CLIENT DELIGHT

Previous

> NAVLIN Price & Access Data is an amazing tool, the data quality, insights, and
> user-friendliness are far superior to any other pricing database I've used in
> my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

> NAVLIN delivers a comprehensive and superior pricing platform offering quality
> and reliable data, strategic insights, and a dedicated team of individuals who
> are best in class - true partners in every aspect.

Vylynh Vo

Head, Global Value Strategy & Policy @ Atara Biotherapeutics

> I've been singing the praises of EVERSANA to everyone! NAVLIN Price & Access
> Data is truly amazing!

Senior Director

Market Access

> My team literally could not do what they do without NAVLIN Price & Access
> Data.

Senior Director

Senior Director, Global Value Strategy & Policy

> To say thank you seems so trivial. I really appreciate all the hard work and
> time that you all have invested.

Vice President

Global Pricing & Market Access

> Your response was quicker than I have received from any other pricing data
> providers. I really appreciate your help at 11 PM :)

Head

Global Value Strategy & Policy

> The customer service is amazing - knowledgeable, friendly, and responsive.
> Every time I need assistance I am always impressed.

Information Analyst

Global Pricing & Market Access

> Accurate and fast response, exactly what I needed, could not ask for more.

Head

Pricing and Health Outcomes

> I recently had the pleasure of using the NAVLIN Tender Data Service for a
> project. The data was spot on and saved me a lot of time, allowing me to focus
> on data analysis instead of data collection.

Global Marketing Director Rx

Medis, Medical Marketing Company

Next
Trusted and utilized daily by thousands of global pharma market access
professionals.
Focused customer support, and product innovation resulted in a 99.8% Customer
satisfaction rating (CSAT) over 12 months.
Promoted achieved top quartile Net Promoter Score (NPS) when surveyed across
global customers.
Efficient NAVLIN is beautifully designed and easy to use - reducing research
time and helping you make better, more informed decisions.
Promoted achieved top quartile Net Promoter Score (NPS) when surveyed across
global customers.
Efficient NAVLIN is beautifully designed and easy to use - reducing research
time and helping you make better, more informed decisions.
Trusted and utilized daily by thousands of global pharma market access
professionals.
Focused customer support, and product innovation resulted in a 99.8% Customer
satisfaction rating (CSAT) over 12 months.
Promoted achieved top quartile Net Promoter Score (NPS) when surveyed across
global customers.
Efficient NAVLIN is beautifully designed and easy to use - reducing research
time and helping you make better, more informed decisions.
Trusted and utilized daily by thousands of global pharma market access
professionals.
Focused customer support, and product innovation resulted in a 99.8% Customer
satisfaction rating (CSAT) over 12 months.
 * 1
 * 2
 * 3
 * 4

NAVLIN DAILY


CHECK OUT TODAY’S NEWS

Previous


NICE RECOMMENDS VERTEX'S CASGEVY FOR BETA-THALASSAEMIA VIA IMF MANAGED ACCESS

In its final draft guidance, the National Institute for Health and Care
Excellence (NICE) has recommended Vertex's Casgevy (exagamglogene autotemcel),
the world's first CRISPR-based gene therapy, for individuals aged 12 and over
with severe beta-thalassaemia who require regular blood transfusions and are
eligible for a blood and bone marrow transplant but lack a suitable donorNICE
acknowledges uncertainty in the clinical evidence and suggests that collecting
more data through a managed access agreement via the Innovative Medicines Fund
(IMF) may help resolve some of these uncertaintiesThe treatment costs £1,651,000
per course at its list price, but the company has a commercial arrangement,
including a managed access agreement and a commercial access agreement

Aug 08,2024
   
 * C&G Therapy
   
 * HTA
   
 * Pricing & Reimbursement
   


MHRA APPROVED 52 NEW AND 494 GENERIC PRODUCTS LAST YEAR

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released
its 2023/2024 Annual Report, in which it recaps highlights from the Agency’s
last working year. Notables include Mounjaro for weight loss, Tepkinly for
lymphoma, Litfulo for alopecia, Jemperli for advanced endometrial cancer, and
Casgevy for sickle cell disease via CRISPR techThe report mentions progress on
the International Recognition Procedure (IRP), a new approval pathway for UK.
Through this, the MHRA can use decisions from trusted reference regulators,
including from the U.S., EU, and Singapore. All applications reviewed through
this pathway to date have met their target deadlines According to the report,
applications assessed through the IRP pathway have been approved 100% within
target timelines. However, the group is working with other UK-based bodies to
develop revised eligibility criteria for the Innovative Licensing and Access
Pathway (ILAP), as there were just 57 applications for the in the year ending 31
March 2024, down from 178 the previous year

Aug 05,2024
   
 * Drug Approval
   


G-BA TEMPORARILY SUSPENDS BENEFIT ASSESSMENT FOR JANSSEN’S CARVYKTI FOR 8 MONTHS
AFTER SURPASSING EUR 30 MILLION THRESHOLD

The Federal Joint Committee (G-BA) decided to temporarily suspend the benefit
assessment for Janssen’s Carvykti (ciltacabtagene autoleucel) for its newly
added indication for treating adult patients with relapsed and refractory
multiple myeloma who have undergone at least one therapy and are refractory to
lenalidomideThe suspension was prompted by the company's report on June 13,
2024, indicating that Carvykti sales exceeded EUR 30 million in the first
quarter of 2024The temporary suspension will end no later than eight months
after G-BA requests additional evidence of Carvykti's benefit compared to
appropriate comparator therapies

Jul 26,2024
   
 * C&G Therapy
   
 * HTA
   
 * Pricing & Reimbursement
   


ELI LILLY TO OFFER STARTER DOSES OF ZEPBOUND FOR $399, $549 PER MONTH

Eli Lilly has started selling its weight loss medicine, Zepbound (tirzepatide),
in single-dose vials of 2.5mg and 5mg through LillyDirect at a signficant
discountThe prices for these doses will cost consumers $399 to $549 per month,
respectively. This represents a $250 discount compared to the $650 per month
Lilly currently charges patients for the pen version of ZepboundThe decision is
also expected to increase the availability of Zepbound, which is usually sold in
auto-injector pens and has been facing supply issues over the past year

Aug 28,2024
   
 * Drug Launch
   
 * Other
   


MEET US AT THE WORLD ORPHAN DRUG CONGRESS EUROPE 2024!

We are pleased to announce that NAVLIN Daily is an official media partner with
the World Orphan Drug Congress (WODC) Europe, taking place October 22-25, 2024,
in everyone’s favorite sunny Barcelona!The event convenes leading pharmaceutical
and biotech companies, government and regulatory authorities, patient advocacy
groups, payers, investors and solution providers to meet and brainstorm ways to
advance orphan drug development and improve access to life-saving therapiesAs a
valued NAVLIN Daily customer, you can use our ND50 registration discount code
for an exclusive 50% discount

Aug 21,2024
   
 * Conferences
   


DAK GESUNDHEIT REPORT FINDS “BLIND SPOTS” IN AMNOG

DAK Gesundheit has released its 2024 report, highlighting the rising costs of
patented medicine in Germany. The report notes an 18% rise in spending, compared
to the same period in 2023The report issues updates on all the key measures of
the Financial Stabilization Act (GKV-FinStG), including the controversial
guardrails, the orphan drug threshold and combination discounts Based on its
findings, DAK Gesundheit calls for a critical reassessment of recent reforms and
for the introduction of more robust transparency measures, particularly in
hospital drug spending

Aug 19,2024
   
 * Pricing & Reimbursement
   
 * Policy
   


CMS PUBLISHES LONG-AWAITED DRUG PRICES FROM FIRST ROUND OF MEDICARE NEGOTIATIONS

The Biden Administration published its long-awaited final prices for the first
ten prescription drugs selected for negotiation under the Inflation Reduction
Act (IRA), with discounts ranging from 47-80% compared to current list prices
obtained through NAVLIN Price & Access Data (versus CMS’ use of 2023 list
prices)Although the published prices establish a starting point for Medicare’s
new ability to negotiate with manufacturers and provide useful insight for
future rounds of negotiation, several questions about the program and its
long-term impact remainKey developments to watch as prices are implemented
include: whether or not most beneficiaries in Medicare Part D will directly
benefit from the savings generated by Medicare-negotiated discounts; how
pharmacy benefit managers (PBMs) and insurers will respond to negotiated prices;
and whether CMS will implement any safeguards to ensure that PBMs and plans
maintain beneficiary access to drugs selected for negotiation

Aug 16,2024
   
 * Pricing & Reimbursement
   
 * Policy
   


SPANISH MOH RELEASES DRAFT DECREE ON HTA

After much anticipation, the Spanish Ministry of Health has released the draft
Royal Decree regulating the assessment of health technologies, which clearly
separates clinical evaluations from non-clinical assessmentsThe new regulation
is based on nine key considerations: four clinical criteria, including
healthcare issue identification, technical analysis, safety, and efficacy, and
five non-clinical factors, such as cost, ethical, organizational, social, and
legal aspectsThe public consultation on the draft will remain open until
September 20, 2024

Aug 14,2024
   
 * HTA
   
 * Pricing & Reimbursement
   


ABPI CALLS FOR CHANGES TO NICE'S SEVERITY MODIFIER

The Association of the British Pharmaceutical Industry (ABPI) has raised
concerns about the National Institute for Health and Care Excellence’s (NICE)
severity modifier, which is used to prioritize treatments for severe
conditionsIn a recent blog post, the ABPI suggests NICE's goal of keeping the
severity modifier financially neutral is limiting broader patient access to
these treatments. The group also asserts that the severity modifier is being
applied too conservatively. As a result, some cancer treatments that were
previously eligible for consideration under the end-of-life modifier are now
failing to qualify for the highest severity weighting, thereby preventing some
patients from accessing potential life-extending treatmentsTo resolve this, the
ABPI suggests that NICE revise the severity modifier by lowering severity cutoff
levels, so more medicines can get higher weightings. It also urges NICE to
abandon the cost-neutral approach in favor of an evidence-based method that
prioritizes treatments for severe diseases as per societal preferences.

Aug 14,2024
   
 * HTA
   
 * Pricing & Reimbursement
   
 * Cost Effectiveness
   
 * Policy
   


SMC BACKS HEMGENIX AND LONSURF

The Scottish Medicines Consortium (SMC) has given interim approval for Hemgenix
(etranacogene dezaparvovec) for adults with haemophilia B, allowing its use
while additional evidence is collected; the move follows the National Institute
for Health and Care Excellence's (NICE) recommendation for the gene therapy SMC
Chair Dr Scott Muir highlighted the balance between optimism for Hemgenix due to
promising clinical evidence, and the need for further research into long-term
effectiveness, adding: "The committee look forward to reviewing the updated
evidence when available to ensure that this treatment offers good value to
patients in NHSScotland"In the same meeting, the SMC also approved Lonsurf
(trifluridine/tipiracil) in combination with bevacizumab for adults with
advanced colorectal cancer who have undergone two prior treatments

Aug 13,2024
   
 * C&G Therapy
   
 * Managed Entry Agreements
   
 * Pricing & Reimbursement
   


NICE RECOMMENDS VERTEX'S CASGEVY FOR BETA-THALASSAEMIA VIA IMF MANAGED ACCESS

In its final draft guidance, the National Institute for Health and Care
Excellence (NICE) has recommended Vertex's Casgevy (exagamglogene autotemcel),
the world's first CRISPR-based gene therapy, for individuals aged 12 and over
with severe beta-thalassaemia who require regular blood transfusions and are
eligible for a blood and bone marrow transplant but lack a suitable donorNICE
acknowledges uncertainty in the clinical evidence and suggests that collecting
more data through a managed access agreement via the Innovative Medicines Fund
(IMF) may help resolve some of these uncertaintiesThe treatment costs £1,651,000
per course at its list price, but the company has a commercial arrangement,
including a managed access agreement and a commercial access agreement

Aug 08,2024
   
 * C&G Therapy
   
 * HTA
   
 * Pricing & Reimbursement
   


MHRA APPROVED 52 NEW AND 494 GENERIC PRODUCTS LAST YEAR

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released
its 2023/2024 Annual Report, in which it recaps highlights from the Agency’s
last working year. Notables include Mounjaro for weight loss, Tepkinly for
lymphoma, Litfulo for alopecia, Jemperli for advanced endometrial cancer, and
Casgevy for sickle cell disease via CRISPR techThe report mentions progress on
the International Recognition Procedure (IRP), a new approval pathway for UK.
Through this, the MHRA can use decisions from trusted reference regulators,
including from the U.S., EU, and Singapore. All applications reviewed through
this pathway to date have met their target deadlines According to the report,
applications assessed through the IRP pathway have been approved 100% within
target timelines. However, the group is working with other UK-based bodies to
develop revised eligibility criteria for the Innovative Licensing and Access
Pathway (ILAP), as there were just 57 applications for the in the year ending 31
March 2024, down from 178 the previous year

Aug 05,2024
   
 * Drug Approval
   


G-BA TEMPORARILY SUSPENDS BENEFIT ASSESSMENT FOR JANSSEN’S CARVYKTI FOR 8 MONTHS
AFTER SURPASSING EUR 30 MILLION THRESHOLD

The Federal Joint Committee (G-BA) decided to temporarily suspend the benefit
assessment for Janssen’s Carvykti (ciltacabtagene autoleucel) for its newly
added indication for treating adult patients with relapsed and refractory
multiple myeloma who have undergone at least one therapy and are refractory to
lenalidomideThe suspension was prompted by the company's report on June 13,
2024, indicating that Carvykti sales exceeded EUR 30 million in the first
quarter of 2024The temporary suspension will end no later than eight months
after G-BA requests additional evidence of Carvykti's benefit compared to
appropriate comparator therapies

Jul 26,2024
   
 * C&G Therapy
   
 * HTA
   
 * Pricing & Reimbursement
   


ELI LILLY TO OFFER STARTER DOSES OF ZEPBOUND FOR $399, $549 PER MONTH

Eli Lilly has started selling its weight loss medicine, Zepbound (tirzepatide),
in single-dose vials of 2.5mg and 5mg through LillyDirect at a signficant
discountThe prices for these doses will cost consumers $399 to $549 per month,
respectively. This represents a $250 discount compared to the $650 per month
Lilly currently charges patients for the pen version of ZepboundThe decision is
also expected to increase the availability of Zepbound, which is usually sold in
auto-injector pens and has been facing supply issues over the past year

Aug 28,2024
   
 * Drug Launch
   
 * Other
   


MEET US AT THE WORLD ORPHAN DRUG CONGRESS EUROPE 2024!

We are pleased to announce that NAVLIN Daily is an official media partner with
the World Orphan Drug Congress (WODC) Europe, taking place October 22-25, 2024,
in everyone’s favorite sunny Barcelona!The event convenes leading pharmaceutical
and biotech companies, government and regulatory authorities, patient advocacy
groups, payers, investors and solution providers to meet and brainstorm ways to
advance orphan drug development and improve access to life-saving therapiesAs a
valued NAVLIN Daily customer, you can use our ND50 registration discount code
for an exclusive 50% discount

Aug 21,2024
   
 * Conferences
   


DAK GESUNDHEIT REPORT FINDS “BLIND SPOTS” IN AMNOG

DAK Gesundheit has released its 2024 report, highlighting the rising costs of
patented medicine in Germany. The report notes an 18% rise in spending, compared
to the same period in 2023The report issues updates on all the key measures of
the Financial Stabilization Act (GKV-FinStG), including the controversial
guardrails, the orphan drug threshold and combination discounts Based on its
findings, DAK Gesundheit calls for a critical reassessment of recent reforms and
for the introduction of more robust transparency measures, particularly in
hospital drug spending

Aug 19,2024
   
 * Pricing & Reimbursement
   
 * Policy
   

Next
Read more at NAVLIN DAILY
NAVLIN Data Web API


CREATE POWERFUL DATA EXPERIENCES

Built by developers for developers. With access to millions of data points,
organizations can seamlessly integrate NAVLIN data into internal data lakes,
build custom reports, analog analysis, drug price reports, competitor and
comparator evaluations, or anything else that strikes your fancy.

 * Industry standard RESTful API
 * Access data from any NAVLIN module
 * Build custom dashboards or integrate with internal databases, data lakes, and
   more!
 * Selected by dozens of leading integrators and pharma orgs for its
   best-in-class data structure



Scalable Highly scalable and customizable REST API supports high volumes of
requests by utilizing a dedicated global infrastructure in an ISO 27001
certified data center.
Structured Data Selected by dozens of leading integrators and pharmaceutical
organizations for its best-in-class data structure.
Dedicated Support Dedicated Support is available 24/7, along with detailed
documentation. In just a few hours your application will be up and running!
Dedicated Support Dedicated Support is available 24/7, along with detailed
documentation. In just a few hours your application will be up and running!
Scalable Highly scalable and customizable REST API supports high volumes of
requests by utilizing a dedicated global infrastructure in an ISO 27001
certified data center.
Structured Data Selected by dozens of leading integrators and pharmaceutical
organizations for its best-in-class data structure.
Dedicated Support Dedicated Support is available 24/7, along with detailed
documentation. In just a few hours your application will be up and running!
Scalable Highly scalable and customizable REST API supports high volumes of
requests by utilizing a dedicated global infrastructure in an ISO 27001
certified data center.
 * 1
 * 2
 * 3

Ecosystem


NAVLIN PRICE & ACCESS SOFTWARE IS PART OF THE COMPREHENSIVE NAVLIN PRICE &
ACCESS ECOSYSTEM

Global Scale


THE LEADING PROVIDER OF GLOBAL COMMERCIAL SERVICES

EVERSANA™ is the leading provider of global commercial services to the life
sciences industry. Our integrated solutions are rooted in the patient experience
and span all stages of the product life cycle to deliver long-term, sustainable
value for patients, prescribers, channel partners and payers. We serve more than
500 organizations, including innovative start-ups and established pharmaceutical
companies to advance life science solutions for a healthier world.

40+ Global Locations
500+ Life Science Clients
100% Of the top 25 Bio-Pharma Companies
6,000+ Employees
570+ MDS, RNs, PharmDs
80+ Countries Served
Contact Us


CONNECT WITH OUR TEAM
OF GLOBAL EXPERTS

Feel free to get in touch with us via email, live chat, or book a meeting!

Live Chat Book a Meeting info@navlin.com
NAVLIN
 * NAVLIN Data
 * NAVLIN Software
 * NAVLIN Insights
 * NAVLIN DAILY
 * Book a Meeting

Eversana
 * About Us
 * Solutions
 * Careers
 * News
 * Contact Us


SUBSCRIBE TO MONTHLY NEWSLETTER

By subscribing, you agree to EVERSANA’s term & conditions and privacy policy.
Subscribe
 * Eversana
 * LinkedIn

© 2024 EVERSANA. All Rights Reserved.
Privacy Policy  |  Terms & Conditions




SUCCESS

Handle Success

Got it, thanks!